• Wondering if Acadia Healthcare Company at around US$27.85 is a bargain or a value trap? This article walks through what the current price might be implying.
• The stock has returned 1.7% over the past week, 16.2% over the last month, 94.9% year to date and 19.5% over the past year, while the 3 year and 5 year returns of 59.7% and 56.5% declines show that longer term holders have had a very different experience.
• Recent coverage has focused on Acadia Healthcare Company as a specialist in behavioral health facilities, with attention on how its footprint and acquisition activity position it within the US healthcare sector. At the same time, market commentary has highlighted how investor sentiment around healthcare services and policy funding can influence stocks like Acadia, which provides useful context for the recent price moves.
• Right now, Acadia Healthcare Company has a valuation score of 5 out of 6. The next sections will compare different valuation methods to see what the current market price might be factoring in and then finish with a framework that can help you judge these signals more effectively.

Approach 1: Acadia Healthcare Company Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes estimates of the cash a company could generate in the future and discounts those amounts back to today to arrive at an implied value per share.

For Acadia Healthcare Company, the latest twelve month free cash flow (FCF) is a loss of $418.7 million. Despite that, the model uses a 2 Stage Free Cash Flow to Equity approach, combining analyst inputs and extrapolated figures. For example, FCF for 2026 is projected at $34.2 million and for 2027 at $127.3 million, with further estimates stepping up over time to a projected $581.2 million in 2035. All figures are in $ and amounts remain below $1b, so are expressed in millions.

Aggregating and discounting these projected cash flows results in an estimated intrinsic value of about $102.89 per share. Compared with the recent share price around $27.85, this DCF output suggests Acadia Healthcare Company trades at a 72.9% discount to that intrinsic estimate, which screens as materially undervalued on this model.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Acadia Healthcare Company is undervalued by 72.9%. Track this in your watchlist or portfolio, or discover 50 more high quality undervalued stocks.

Approach 2: Acadia Healthcare Company Price vs Sales

For companies where profitability is mixed or where margins can fluctuate, the P/S ratio is often a useful cross check because it compares the share price to the revenue base rather than earnings. It helps you judge what investors are currently willing to pay for each dollar of sales.

In general, higher expected growth and lower perceived risk can justify a higher P/S ratio, while slower growth and higher uncertainty tend to support a lower “normal” range. So the context around the business model and balance sheet really matters when you compare multiples.

Acadia Healthcare Company currently trades on a P/S of 0.76x. The broader Healthcare sector average is around 1.21x and the peer group average is about 1.20x, so the shares trade below both of those benchmarks. Simply Wall St’s proprietary “Fair Ratio” for Acadia Healthcare Company is 1.22x, which reflects factors such as its growth profile, industry, profit margins, market value and specific risks. This Fair Ratio can be more informative than a simple peer or industry comparison because it is tailored to the company’s own characteristics rather than broad group averages. Comparing 0.76x to the Fair Ratio of 1.22x suggests the shares are undervalued on this metric.

Result: UNDERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 17 top founder-led companies.

Upgrade Your Decision Making: Choose your Acadia Healthcare Company Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you attach a clear story to your numbers by connecting your view on Acadia Healthcare Company’s future revenue, earnings and margins to a financial forecast, a fair value, and then a simple comparison with the current price. All of this is available inside an accessible tool on the Community page that updates automatically when fresh news or earnings are released. One investor might build a cautious Narrative that lines up closer to a Fair Value around US$14 based on lower assumed growth and a P/E of about 8.5x. Another might prefer a more optimistic Narrative closer to US$49.43 that assumes stronger growth, higher earnings and a P/E of about 15x. This gives you a clear way to see which story you agree with and what that implies for whether Acadia looks expensive or cheap on your terms.

Do you think there's more to the story for Acadia Healthcare Company? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.